Please wait while the formulary information is being retrieved.
CINQAIR (RESLIZUMAB)
- Eosinophilic asthma
10 mg/mL intravenous solution
- Infuse 3 mg/kg over 20-50 minute(s) by intravenous route every 4 weeks
Eosinophilic asthma
- Infuse 3 mg/kg over 20-50 minute(s) by intravenous route every 4 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- Acutely deteriorating asthma
Contraindicated
- Parasitic infection
Severe
Moderate
- None
CINQAIR (RESLIZUMAB)
- Eosinophilic asthma
- None
- Increased creatine kinase level
- Sore throat
More Frequent
Severe
Less Severe
- None
- Fatigue
- Muscle spasm
- Musculoskeletal pain
- Myalgias
- Neck pain
- Non-cardiac chest pain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Malignancy
Less Severe
- None
Contraindicated
None
Severe Precaution
Reslizumab
Increased risk of asthma exacerbation. Not indicated per manufacturer.
- 1 Day – 18 Years
- Increased risk of asthma exacerbation. Not indicated per manufacturer.
Management or Monitoring Precaution
None
Reslizumab
- Severity Level:
2
- Additional Notes: Insuff human data avail; monoclonal antibodies cross placenta
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Reslizumab
Insufficient human data avail; igg known to be excreted
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data avail; igg known to be excreted |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication may rarely cause a serious allergic reaction. You should receive this medication in a hospital or clinic so your doctor can watch you closely and lessen the risk. Get medical help right away if you notice any symptoms of a serious allergic reaction such as rash, flushing, itching/swelling (especially of the face/tongue/throat), severe dizziness, or trouble breathing.
| Eosinophilic asthma | |
| J82 | Pulmonary eosinophilia, not elsewhere classified |
| 0-9 | A-Z |
|---|---|
| J82 | Pulmonary eosinophilia, not elsewhere classified |
Formulary Reference Tool